Analysis of the current situation and trend of antineoplastic plant drugs

Cancer has been a serious threat to human health in recent years, the global anti-tumor drug market has been growing According to the survey data, the market scale of anti-tumor drugs in China reached 49.126 billion yuan in 2010, up 21.30% year on year In the ranking of hospital drug use, antineoplastic drugs have jumped from the fourth place in 2002 to the second place in 2010, only next to anti infective drugs, accounting for 17.6% of the market share of hospital drug use, 5% higher than five years ago In recent years, the data show that plant medicine anti-tumor has been in a high trend, but the development is slow The development of market-oriented star products is slowing down, and only a few single products have seen rapid growth What are the bottlenecks and opportunities for the future development of botanical drugs? According to the data of China Market Research Center, among many anti-tumor drugs, the share of plant anti-tumor drugs has been at the top of all kinds of anti-tumor drugs, and the latest data shows that its market share has increased to 37.14% in 2010 In China's anti-tumor drug market, the plant alkaloids and other natural drugs with good sales are paclitaxel, hydroxycamptothecin, vinorelbine, docetaxel, etc These drugs not only play a major role in interfering with the synthesis of cancer cell microprotein, but also have the positive role of inducing apoptosis and anti angiogenesis, and have an irreplaceable position in anti-tumor drugs The high clinical demand of this kind of drugs promotes the hot market of its upstream API At the same time, new products are also emerging According to the data of China Pharmaceutical Industry Information Center, the sales amount of anti-tumor botanical drugs slowed down in 2011, and the growth level of each anti-tumor botanical drug is different Apart from star products, which products have new market anti-cancer value? From the analysis of import and export data to the current situation analysis and development trend of domestic and foreign markets, Bio Valley invites Let's invite Zhang Zhongpeng, deputy director of China Chamber of Commerce for the import and export of pharmaceutical and health care products, Huaiping, market analysis teacher of Shanghai Pharmaceutical Industry Research Institute, to participate in 2012 anti tumor botanical drug industry development forum, and make an analysis of the market situation of China's plant anti-tumor drugs Natural medicine has a good effect in reducing clinical symptoms, improving the quality of life, preventing recurrence and metastasis, prolonging the survival period, cooperating with radiotherapy and chemotherapy, increasing efficiency and reducing toxicity Of the 175 anticancer drugs used in the world, 57% are directly or indirectly derived from natural products However, only 6% of them have been screened for bioactivity, 15% of them have been evaluated by phytochemistry, and less than 10% of them have been studied in detail Therefore, the potential of natural products to develop innovative drugs is huge Combined with the combination of Western medicine, the clinical effect has also been significantly improved No matter from drug activity screening, clinical safety assessment or EU registration and approval, it is inseparable from the clinical effect The above-mentioned relevant letters are respectively written by Yu Qiang, Professor of Shanghai Pharmaceutical Research Institute of Chinese Academy of Sciences, Yang Yi, director of clinical research and development of Sanofi, ye Zuguang, Professor of Chinese Academy of traditional medicine and Liang Yi, Professor of China Pharmaceutical University I will explain it in detail Paclitaxel and docetaxel are two leading plant antitumor drugs, paclitaxel is a new natural plant antitumor drug In the late 1960s, the National Cancer Institute (NCI) of the United States extracted paclitaxel from the bark of paclitaxel brevifolium After isolation, the diterpenoids with paclitaxel ring were obtained After more than 30 years of development by NCI and Squibb, it was approved by FDA in December 1992, and its trade name is taxol It has been listed in more than 50 countries in the world, mainly used for the treatment of ovarian cancer, breast cancer, non-small cell lung cancer and kaporo type cancer Docetaxel belongs to microtubule depolymerization inhibitor, which is not a natural substance and must be produced in a semi synthetic way This product is a semi synthetic taxol derivative developed by French company Ronald Planck lean This product is mainly injection, supplemented by powder injection and capsule It is a chemotherapy drug for breast cancer and non-small cell lung cancer According to bioinsight data, taxol and docetaxel occupy the top 10 anti-tumor drugs There are two kinds of paclitaxel APIs on the international market: one is from the bark of various Taxus; the other is from the branches of European ornamental Taxus to extract 10-berry gibberelline, which is then semi synthesized, namely docetaxel and carbataxel Taxus chinensis is a kind of plant with high economic, ecological and scientific research value, and its wild resources are very precious With the maturity of artificial cultivation technology, the planting scale of artificial Taxus chinensis in China is expanding day by day, but there are also disadvantages in the field of market planting How to plan planting and production specifications reasonably is expected to be concerned and discussed by all At present, the methods to obtain taxol are: natural extraction, artificial synthesis, artificial semi synthesis, biological fermentation and cell culture Among them, the artificial semi synthesis technology of taxol has been very mature, accounting for the vast majority of its output However, at present, asymmetric catalytic reactions or chiral sources are generally used in the synthesis of paclitaxel and polyene paclitaxel at home and abroad Zhang Shengyong, academician of the Chinese Academy of engineering of the Fourth Military Medical University, and Li Yaping, researcher of Shanghai Institute of pharmaceutical research of the Chinese Academy of Sciences, will give a speech on the artificial semi synthesis of taxane and the development of new dosage forms at the 2012 anti-tumor botanical drug industry development forum At present, some domestic manufacturers have successfully developed and used cell culture method to produce paclitaxel by batch culture of paclitaxel bark cells in factories With the continuous improvement of technology, it is believed that taxol production will further expand In the past, traditional plant anti-tumor drugs have been used in the treatment of cancer and other indications, such as the application of paclitaxel in the treatment of rheumatoid arthritis and paclitaxel eluting drug stent The Organizing Committee of 2012 anti tumor botanical medicine industry development forum made a special discussion on the endangered plant giant panda, Taxus chinensis Experts from the Institute of Botany will give guidance and evaluation on the development and utilization of artificial planting The new research results of plant anti-tumor drugs are constantly facing the treasure house of plant drugs, and scientists at home and abroad have been studying and exploring In recent years, scientists have successively isolated and extracted effective anti-tumor ingredients from many plants, such as camellia, silymarin, chickpea, triptolide, Artemisia annua, elemene and so on In the future, anti-tumor star products are constantly emerging In the face of new market orientation and expiration of related patents, what impact will the new products bring to traditional products? In the face of the export form of overseas market, what kind of test will China's existing resources face? How to solve a series of problems, such as the shortage of domestic raw material market supply and price regulation? What business opportunities and challenges will new anti-cancer varieties bring to enterprises? Chen Guoqiang, Dean of Medical School of Shanghai Jiaotong University, Zeng Jinzhang, Vice Dean of School of pharmacy of Xiamen University, and Xie Tian, director of Dalian Huali Jingang Pharmaceutical Co., Ltd further discuss this with you! From September 26 to 27, 2012, the "2012 anti tumor botanical drug industry development forum" hosted by Biovalley will be held in Shanghai The conference will focus on "market analysis and future forecast of raw materials and preparations of plant anti-tumor drugs", "development analysis of anti-tumor drug market in new policy of medical reform", "resource utilization and development of plant anti-tumor drugs", "European approval and quality standard of traditional botanical drugs" With the theme of "quasi strategy" and "overview of the latest development of anti-tumor botanical drugs", the industry associations / societies, botanical drug manufacturers (upstream and downstream industry chains), medical and clinical testing and testing institutions, scientific research institutes, instrument and equipment suppliers, legal consulting institutions and other domestic and foreign counterparts are invited to exchange industry experience, share the latest information, and explore the field of traditional botanical anti-tumor drugs Opportunities and challenges.